What are the benefits of #IVUS-guided #DCB angioplasty in de novo lesions? 🤔
Check out the results of the ULTIMATE III trial in this issue of #JACCINT: https://t.co/l9uJOVzngQ
In patients undergoing valve-in-valve (ViV) interventions for failed surgical bioprosthetic valves, performing bioprosthetic valve fracture (BVF) after transcatheter heart valve (THV) implantation, compared to BVF performed before THV implantation or no BVF, resulted in better immediate hemodynamic performance and sustained valve function without long-term trade-offs in THV performance or structural valve damage, as demonstrated in bench studies simulating up to 5 years of valve wear.#EIJBestOf
@David_Meier_@sellers_steph
👉https://t.co/55DP7TIn1R
You may have heard of the "5-6-7-8" rule for LM-LAD-LCx stent MSAs to reduce long term MACE, but this new study in @CircIntv suggests that bigger MSAs are needed.
A new "6-8-12" rule?
https://t.co/nP8fr4Vx13).
Patient was referred to our centre for CABG due to significant proximal and mid LAD disease. Review of diagnostic angio showed this. What do you think might have happened here
Contemporary issues of percutaneous coronary intervention in heavily calcified chronic total occlusions: an expert review from the European CTO Club. #EIJBestOf https://t.co/8uucIzDl3R
In the REVIVED-BCIS2 (Revascularization for Ischemic Ventricular Dysfunction) trial, PCI did not reduce the incidence of death or hospitalization for heart failure (HHF). Similarly, in a recent prespecified secondary analysis, PCI did not improve the hierarchical composite of death, HHF, and health status at 2 years. PCI improved KCCQ-OSS at 6 months, but this benefit was not sustained to 1- or 2-year follow-up https://t.co/l0hRcmmnyp @JACCJournals
Warning: for novice US DCB users! DCB are not non compliant! Here is a perforation i had with a 3.5 DCB after taking it to its nominal 14 Bar pressure( it grew to 4) after an uneventful NC PTCA using NC quantum 3.5/15 at 28 Bar!
Watch ur size chart!
Do you "wedge" the PA catheter in the CICU because you don't trust the surrogate PA diastolic?
Compelling safety reasons to avoid doing this.
A new study in @JCardFail validating the use of PA diastolic for most patients with left-sided predominant CS.
https://t.co/wbkM7Obf2h
We’re coming closer to enrollment completion for the #STAR trial led by Taishi Hirai & @KateKearney4.
Hopefully it’ll confirm the safety and efficacy of a 2-step #CTO recanalization in case of impending failure or to avoid risky epicardial collaterals, like this one 👇🏻.
Obstructive CAD Can Be Left Alone Before TAVI, Observational Data Suggest https://t.co/6qkEYT1M3J thx @michaelTCTMD for asking me to chime into this timely question @TCTMD@mmamas1973
Update data from a post hoc secondary analysis of the #STRONG-HF trial
📍In 515 patients, over 90% received medium-to-high doses of #GDMT just 2 weeks post-discharge.
📍⤵️ readmission and death rates in 6 months + better #QoL
📍Rapidly optimizing doses of 4 pillars HF meds was feasible and safe in most patients, and crucial for better outcomes in #AHF patients.
https://t.co/MwF8O3KkBa @JAMACardio #HeartFailure
An excellent way to cross retrogradely is to telescope an angled glide catheter through 6F and cross it using a straight wire. Learned from @tjsimard. @benhibbertMDPhD
Do you know the presentation, management, and outcomes of very late sinus sequestration in native aortic annuli? If not, learn about it in #JACCCaseReports: https://t.co/CJ3YxIcy8T
#TAVI#TAVR#CardioTwitter